Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorevunersen (STK-001) open-label extension in Dravet syndrome
NCT04740476Phase 2Active, not recruiting
- Sponsor
- Stoke Therapeutics
- Start
- Jan 2021
- Primary completion
- Mar 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zorevunersen in Dravet syndrome, sponsored by Stoke Therapeutics. Primary endpoint: Safety of multiple doses of zorevunersen. Started Jan 2021; status: active, not recruiting.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT04740476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740476.